Biocon Limited

rs,

7, 2023 To, The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523 Dear Sir/Madam, Subject: Investor Presentati

₹ 8,397

O C O N L I M I T E D B I O C O N L I M I T E D B I O C O N L I M I T E D 2 2 Biocon at a Glance ₹ 8,397 Cr | $ ~1.1 bn Revenue* ~15,000+ Total Employees* Rank #8 Among Top 10 Global Biotech Employers*

rs 1

products commercialized globally Hybrid model: Direct presence + Network of partners & distributors 1Two products are in-licensed i.e. Adalimumab & Etanercept B I O C O N L I M I T E D B I O C O N L I

rs 2

o drive sustainable growth B I O C O N B I O L O G I C S G R O W T H D R I V E R S Today < 2 years 2-4 years >4 years - Pegfilgrastim - Trastuzumab - Bevacizumab - Bevacizumab (US) - Aspart (US)

70 Billion

Global Markets 08 20 Biosimilars in our Portfolio Biocon Biologics’ portfolio targets a ~US$ 70 Billion addressable market by FY27 Note: Market size only includes products where there has been company r

53%

✓ $82M raised in Seed/Series A from syndicate of dedicated biotech investors (Biocon ownership at 53%) ✓ Leveraging the Biocon and Syngene infrastructure to offer agility and deep experience in CMC/dr

1,069 %

/2) Consolidated (in INR Cr.) Q3 FY23 Q3 FY22 YoY % Total Revenue 3,020 2,223 Core EBITDA1 1,069 % Margin EBITDA % Margin Profit Before Tax (Before exceptional charge) % Margin Net Profit (Bef

36%

(Before exceptional charge) % Margin Net Profit (Before exceptional charge) Net Profit Margin % 36% 723 24% 246 8% 140 5% 715 33% 537 24% 269 12% 187 8% 36 49 35 (9) Biosimilars +5

24%

ceptional charge) % Margin Net Profit (Before exceptional charge) Net Profit Margin % 36% 723 24% 246 8% 140 5% 715 33% 537 24% 269 12% 187 8% 36 49 35 (9) Biosimilars +54% | Resea

8%

charge) % Margin Net Profit (Before exceptional charge) Net Profit Margin % 36% 723 24% 246 8% 140 5% 715 33% 537 24% 269 12% 187 8% 36 49 35 (9) Biosimilars +54% | Research +23%

5%

% Margin Net Profit (Before exceptional charge) Net Profit Margin % 36% 723 24% 246 8% 140 5% 715 33% 537 24% 269 12% 187 8% 36 49 35 (9) Biosimilars +54% | Research +23% | Generic

33%

Net Profit (Before exceptional charge) Net Profit Margin % 36% 723 24% 246 8% 140 5% 715 33% 537 24% 269 12% 187 8% 36 49 35 (9) Biosimilars +54% | Research +23% | Generics +18% Ne

Research Services

1

Research Services

Syngene has capabilities spanning the value chain, facilitating integration Research business Development and Manufacturing business Discovery Services Dedicated R&D Centres Development Services Manufacturing Services Flexible Platform with capability across multiple modalities, including small molecule, large molecule, peptides, oligonucleotides, antibody drug conjugates, PROTACs SynVent Syngene’s proprietary platform for Integrated Drug Discovery Ring-fenced infrastructure for exclusive operations for an individual client Pre-clinical to clinical trials Manufacturing of small and large molecules for commercial supplies Dedicated, multi-disciplinary team of scientists Access to entire Syngene ecosystem for specialist research and development operations Drug substance and drug product development cGMP-compliant facilities Associated services to demonstrate the safety, tolerability and efficacy of the selected drug candidate cGMP-compliant manufacturing of clinical supplies, and registr